Mast cells and inflammation-associated colorectal carcinogenesis

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Chronic inflammation is closely linked to cancer development, particularly colorectal cancer (CRC).
• Inflammatory bowel disease (IBD) increases CRC risk, with inflammatory mediators from cells like macrophages and mast cells contributing to tumor growth.
• The specific role of mast cells in inflammation-associated CRC remains unclear.

Purpose of the Study:

• To investigate the role of mast cells in the development of inflammation-associated colorectal cancer.
• To determine if mast cell deficiency impacts susceptibility to CRC induced by chemical carcinogens.

Main Methods:

• Utilized mast cell-deficient (WBBF(1)-kit (W/W-v)) and mast cell-normal (WBB6F(1)-+/+(WT)) mice.
• Induced colorectal cancer using azoxymethane (AOM) and dextran sodium sulfate (DSS).
• Assessed inflammation, cytokine mRNA levels, and tumor development via histopathology at 12 and 20 weeks.

Main Results:

• Mast cell-deficient mice exhibited significantly lower colon inflammation scores compared to normal mice.
• Reduced mRNA levels of proinflammatory cytokines and inducible enzymes were observed in mast cell-deficient mice.
• Fewer neoplastic and preneoplastic lesions were found in mast cell-deficient mice, indicating reduced CRC development.

Conclusions:

• Mast cells play a crucial role in promoting inflammation-associated colorectal carcinogenesis.
• Mast cell deficiency confers resistance to CRC development in an inflamed colon.
• Targeting mast cells or their mediators may offer a strategy for preventing or treating inflammation-driven CRC.